Nxstage Medical (NXTM) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
NxStage Reports Second Quarter Financial Results And Raises Full-Year Revenue Guidance
August 4, 2016 8:07 AM EDTLAWRENCE, Mass., Aug. 4, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported second quarter revenue above the top end of its guidance.
Total revenue for the second quarter of 2016 increased 15 percent to $92.2 million, compared with revenue of $80.3 million for the second quarter of 2015. The Company's revenue guidance range for the second quarter was $89.0... More
